CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

NCT ID: NCT06445803

Last Updated: 2024-06-06

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-31
• Study Completion Date: 2026-12-31

Brief Summary

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

Detailed Description

Patients will undergo screening, leukapheresis (cell collection), lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by the anti-CD19 KQ-2002 CAR T cell infusion. The lymphodepleting chemotherapy is administered over 3 days IV to prepare the body for the CAR T cells. The CAR-T cells are infused between 2-7 days after the last dose of chemotherapy. Patients will be followed for two years after the cell infusion on the study and for up to 15 years to monitor for potential long term side effects of cell therapy.

Conditions

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; B-cell Lymphoma Refractory; B-cell Lymphoma Recurrent

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose escalation

CD19/CD22-CAR-transduced T cells at escalating doses (0.5\~5.0 ×10\^6 cells/kg)

Group Type: EXPERIMENTAL

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）

Intervention Type: BIOLOGICAL

CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.

Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.

Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)

Dose expansion

CD19/CD22-CAR-transduced T cells at MTD or highest dose administered

Group Type: EXPERIMENTAL

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）

Intervention Type: BIOLOGICAL

CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.

Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.

Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)

Interventions

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）

CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.

Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.

Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male or female,≥18 years old;
• Histologically confirmed diagnosis of B-ALL or B-NHL(meeting one of the following conditions):

(B-NHL)

1. Second or greater relapse (CD20 regimens must be included) OR

2. Refractory to first-line chemotherapy or relapse within 1 year OR

3. Relapse within 1 year of auto-HSCT.

4. With measurable or evaluable lesions（Dose expansion cohort） (B-ALL)

a. Relapse within 12 months of complete remission on first treatment OR b. Relapse after second-line treatment OR c. Relapse after auto HST OR d. Failure to achieve CR/CRi at the end of induction therapy OR e. Ph+ ALL intolerance to TKI or refractory or relapse after treatment with at least two and more TKIs.

• ECOG 0~2
• Estimated survival time ≥ 12 weeks;
• Main tissues and organs function well.

Exclusion Criteria

• Subjects will be excluded related to the following prior therapy criteria:Prior treatment with bendamustine-containing or fludarabine;Anti-T-cell monoclonal antibody, donor lymphocyte infusion, and CNS radiotherapy within 8 weeks; Chemotherapy, lenalidomide, bortezomib within 2 weeks; vincristine within 1 week; glucocorticoids (prednisone ≥7.5 mg/d or equivalent) within 72 h
• Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
• Uncontrolled, symptomatic, intercurrent illness including but not limited to angina pectoris, cerebrovascular accident or transient ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association (NYHA) classification of ≥ Class III congestive heart failure, severe arrhythmia poorly controlled by medications, hepatic, renal, or metabolic disorders, and hypertension that is uncontrolled by standard therapy；
• active bleeding, or venous thromboembolic event
• Autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that result in end-organ damage or require systemic application of immunosuppressive drugs
• Central nervous system (CNS) disease or symptoms of CNS involvement
• Pregnant or nursing (lactating) women
• Presence of Grade 2 or above non-hematologic toxicity , alopecia and grade 2 neuropathy excluded
• Any Iinappropriate conditions in the opinion of the PI .

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Rong Tao

OTHER

Sponsor Role: lead

Responsible Party

Rong Tao

Chief physician

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Rong Tao, MD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

The First Affiliated Hospital of Nanchang University;

Nanchang, Jiangxi, China

Site Status: RECRUITING

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Weijing Zhang

Role: CONTACT

JJYIN555@163.com

021-64175590 ext. 88503

Facility Contacts

Fei Li, MD

Role: primary

lifeigcp@2022@163.com

13970038386

Rong Tao, MD

Role: primary

rtao@shca.org.cn

8621-64175590

Wenhao Zhang, MD

Role: backup

zwhl98@foxmail.com

8621-64175590

Other Identifiers

KQ-2002-XC001

Identifier Type: -

Identifier Source: org_study_id